hVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale | News Direct

hVIVO chairman Cathal Friel says he remains committed to hVIVO following share sale

hVIVO PLC
News release by hVIVO PLC

facebook icon linkedin icon twitter icon pinterest icon email icon London, UK | February 20, 2024 04:55 AM Eastern Standard Time

 

hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself.

Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions while emphasising his commitment to remain a long-term, supportive shareholder despite this sale.

Friel, who co-founded hVIVO (formerly known as Open Orphan) in 2017, highlighted the company's significant growth and his active involvement in its operations and strategic direction. He mentioned his 25-year experience in mergers and acquisitions (M&A) and his confidence in the company's ability to surpass its medium-term revenue target of £100 million, partly through strategic M&A activities.

Additionally, Friel talked about his new role as Executive Chairman at Poolbeg, a company associated with hVIVO, assuring that this would not diminish his involvement with hVIVO. He shared his enthusiasm for the future of both companies, underscoring his role in identifying market opportunities and assembling high-performing teams to capitalize on them.

 

Contact Details

 

Proactive UK Ltd

 

+44 20 7989 0813

 

uk@proactiveinvestors.com

project media

Tags

HealthPharmaBiotechDrug developmentClinical trialsRare diseases